Zhang Yuan, Yue Hongli, Qin Yirui, Wang Jiajing, Zhao Chenyang, Cheng Miao, Han Bo, Han Ruquan, Cui Weihua
Department of Anesthesiology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, People's Republic of China.
Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, People's Republic of China.
J Pain Res. 2022 Sep 1;15:2619-2628. doi: 10.2147/JPR.S374898. eCollection 2022.
Patients undergoing intraspinal tumor resection usually experience severe postoperative pain. Inadequate postoperative analgesia usually leads to severe postsurgical pain, which could cause patients to suffer from many other related complications. Recently, an increasing number of studies have found that gabapentin can relieve hyperalgesia, postoperative pain, and postoperative inflammation. However, there have been no reports on the use of gabapentin combined with sufentanil preoperatively for acute pain following intraspinal tumor resection.
This is a protocol for a randomized, placebo-controlled, and double-blinded trial. One-hundred and sixty-eight participants with chronic pain related to the intraspinal tumor will be randomized into the gabapentin and placebo groups in a 1:1 ratio. In the gabapentin group, patients will be given 300 mg gabapentin orally 36 h, 24 h, and 12 h before surgery; the placebo group will receive a placebo orally at the same time points preoperatively. To estimate the efficacy and safety endpoints, all the researchers and patients will be blinded until the completion of this study. The primary outcome will be the consumption of sufentanil within 48 h postoperatively. The secondary outcomes include the visual analog scale pain score and Von Frey mechanical pain threshold 36 h and 24 h before and 24 h and 48 h after surgery, the incidence of postoperative nausea, vomiting, and drowsiness, the length of hospital stay and medical expenses.
This trial is to evaluate the efficacy and safety of gabapentin combined with sufentanil for postoperative analgesia in patients who complain of pain before intraspinal tumor resection. The findings will provide a new strategy for multimode perioperative analgesia management in these patients.
接受脊柱内肿瘤切除术的患者通常会经历严重的术后疼痛。术后镇痛不足通常会导致严重的术后疼痛,这可能会使患者出现许多其他相关并发症。最近,越来越多的研究发现加巴喷丁可以缓解痛觉过敏、术后疼痛和术后炎症。然而,尚无关于术前使用加巴喷丁联合舒芬太尼用于脊柱内肿瘤切除术后急性疼痛的报道。
这是一项随机、安慰剂对照、双盲试验方案。168名患有与脊柱内肿瘤相关慢性疼痛的参与者将按1:1的比例随机分为加巴喷丁组和安慰剂组。在加巴喷丁组中,患者将在手术前36小时、24小时和12小时口服300毫克加巴喷丁;安慰剂组将在术前相同时间点口服安慰剂。为了评估疗效和安全性终点,所有研究人员和患者在本研究完成前都将处于盲态。主要结局将是术后48小时内舒芬太尼的消耗量。次要结局包括手术前36小时和24小时、手术后24小时和48小时的视觉模拟评分疼痛评分和von Frey机械性疼痛阈值、术后恶心、呕吐和嗜睡的发生率、住院时间和医疗费用。
本试验旨在评估加巴喷丁联合舒芬太尼用于脊柱内肿瘤切除术前有疼痛主诉患者术后镇痛的疗效和安全性。研究结果将为这些患者围手术期多模式镇痛管理提供一种新策略。